Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Oncologist. 2019 Dec;24(12):e1277-e1285. doi: 10.1634/theoncologist.2019-0096. Epub 2019 Jul 23.
We compared the clinical value of 16a-18F-fluoro-17b-estradiol (F-FES) positron emission tomography (PET)/computed tomography (CT) and F-fluoro-2-deoxy-D-glucose (F-FDG) PET/CT and investigated whether and how F-FES PET/CT affects the implemented management of newly diagnosed estrogen receptor positive breast cancer patients.
We retrospectively analyzed 19 female patients newly diagnosed with immunohistochemistry-confirmed estrogen receptor (ER)-positive breast cancer who underwent F-FES and F-FDG PET/CT within 1 week in our center. The sensitivity of F-FES and F-FDG in diagnosed lesions were compared. To investigate the definite clinical impact of F-FES on managing patients with newly diagnosed ER positive breast cancer, we designed two kinds of questionnaires. Referring physicians completed the first questionnaire based on the F-FDG report to propose the treatment regime, and the second was completed immediately after reviewing the imaging report of F-FES to indicate intended management changes.
In total, 238 lesions were analyzed in 19 patients with newly diagnosed ER-positive breast cancer. Lesion detection was achieved in 216 sites with F-FES PET and in 197 sites with F-FDG PET/CT. These results corresponded to sensitivities of 90.8% for F-FES versus 82.8% for F-FDG PET/CT in diagnosed lesions. Thirty-five physicians were given the questionnaires referring to the treatment strategy, with 27 of them completing both questionnaires. The application of F-FES in addition to F-FDG PET/CT changed the management in 26.3% of the 19 patients with newly diagnosed ER-positive breast cancer.
Performing F-FES PET/CT in newly diagnosed ER-positive breast cancer patients increases the value of diagnosis equivocal lesions and treatment management compared with F-FDG PET/CT.
This study investigated whether 16a-18F-fluoro-17b-estradiol (F-FES) positron emission tomography (PET)/computed tomography (CT) affects the clinical management of patients with newly diagnosed estrogen receptor (ER)-positive breast cancer. Physicians completing two questionnaires comparing the clinical impact of 18F-FES and 18F-FDG on individual management plans in patients with newly diagnosed ER-positive breast cancer confirmed that 18F-FES scans led to change in management in 26.3% of the 19 patients with newly diagnosed ER positive breast cancer. This retrospective study indicates the potential impact of 18F-FES PET/CT on intended management of patients with newly diagnosed estrogen receptor positive breast cancer in comparison to 18F-fluoro-2-deoxy-D-glucose PET/CT.
我们比较了 16a-18F-氟-17b-雌二醇（F-FES）正电子发射断层扫描（PET）/计算机断层扫描（CT）和 F-氟-2-脱氧-D-葡萄糖（F-FDG）PET/CT 的临床价值，并探讨了 F-FES PET/CT 是否以及如何影响新诊断的雌激素受体阳性乳腺癌患者的实施管理。
我们回顾性分析了在我院中心在 1 周内接受 F-FES 和 F-FDG PET/CT 的 19 名新诊断为免疫组织化学证实的雌激素受体（ER）阳性乳腺癌的女性患者。比较了 F-FES 和 F-FDG 在诊断病变中的敏感性。为了研究 F-FES 对管理新诊断的 ER 阳性乳腺癌患者的明确临床影响，我们设计了两种问卷。参考医生根据 F-FDG 报告完成了第一个问卷，提出了治疗方案，然后在查看 F-FES 成像报告后立即完成了第二个问卷，以表明预期的管理变化。
在 19 名新诊断为 ER 阳性乳腺癌的患者中，共分析了 238 处病变。F-FES PET 检测到 216 个部位有病变，F-FDG PET/CT 检测到 197 个部位有病变。这些结果对应于 F-FES 在诊断病变中的敏感性为 90.8%，而 F-FDG PET/CT 的敏感性为 82.8%。35 名医生收到了治疗策略的问卷，其中 27 名医生完成了两份问卷。在新诊断的 ER 阳性乳腺癌患者中，除 F-FDG PET/CT 外，应用 F-FES 改变了 26.3%患者的管理。
在新诊断的 ER 阳性乳腺癌患者中进行 F-FES PET/CT 可提高诊断可疑病变和治疗管理的价值，与 F-FDG PET/CT 相比。
本研究探讨了 16a-18F-氟-17b-雌二醇（F-FES）正电子发射断层扫描（PET）/计算机断层扫描（CT）是否会影响新诊断的雌激素受体（ER）阳性乳腺癌患者的临床管理。比较 F-FES 和 F-FDG 对新诊断的 ER 阳性乳腺癌患者个体管理计划的临床影响的两位医生完成了两份问卷，证实 F-FES 扫描导致 26.3%的新诊断的 ER 阳性乳腺癌患者管理发生变化。这项回顾性研究表明，与 F-FDG PET/CT 相比，F-FES PET/CT 可能对新诊断的雌激素受体阳性乳腺癌患者的预期管理产生影响。
